MC2 Therapeutics is a privately held emerging dermatology and eye care pharmaceutical company.
Using our proprietary PAD™ Formulation technology we are developing a new standard of topical therapies for chronic diseases designed to be a life companion for patients. We strive to provide new therapies that minimizes the impact of the disease in daily life by providing effective relief of symptoms, while being pleasant to use in daily routines. A new experience for patients and an improved benefit to value proposition for payers and physicians.
Studies show that many chronic diseases such as psoriasis, atopic dermatitis, dry eye and skin that are visible on the patient negatively affects the self-esteem and quality of life of many patients. Patient may feel even further stigmatized if their therapy affects their appearance or stain clothes and bedding because it makes their skin greasy and/or shiny or if it is difficult and time consuming to apply.
We are committed to introduce a paradigm shift in topicals by enabling high effective new PAD™ based therapies that patients will want to use everyday.
We are satisfied when patients using PAD™ based drugs feel free to engage with other people and be as active and social as they want during treatment.